The production of recombinant peptides is critical in biotechnology and medicine for treating a variety of diseases. Thus, there is an urgent need for the development of quick, scalable, and cost-effective recombinant protein expression strategies. This study optimizes induction conditions for an insulin precursor, an analog GLP-1 precursor, and a peptide for COVID-19 therapy expression in E. coli using the response surface method. Factors such as pH, temperature, induction time, isopropyl-β-D-thiogalactopyranoside concentration, and optical density significantly influence peptide productivity. Experimental validation supports the effectiveness of these models in predicting peptide yields under optimal conditions. The optimal induction conditions were determined as follows: temperature at 37 °C, pH of the medium 7.0-8.0, induction at the early logarithmic phase of growth, isopropyl-β-D-thiogalactopyranoside concentration of 0.05 mM, and induction time of 6 h. After model validation, the productivity of each peptide producer exceeded 3 g/L. The optimal conditions achieved peptide titers significantly higher than those previously reported, suggesting that this technique is a versatile cultivation technology for the efficient production of different recombinant peptides. In conclusion, our research enhances the understanding of how tailored cultivation conditions can optimize recombinant peptide production efficiency.

ITMO University St Petersburg 197101 Russia

Pharm Holding St Petersburg P Strelna 34 A Svyazi Street 198515 Russia

Zobrazit více v PubMed

Basu A, Li X, Leong SS (2011) Refolding of proteins from inclusion bodies: rational design and recipes. Appl Microbiol Biotechnol 92:241–251. https://doi.org/10.1007/s00253-011-3513-y PubMed DOI

Belgi A, Hossain MA, Tregear WG, Wade G, Wade D (2011) The chemical synthesis of insulin: from the past to the present. Immun Endocr Metab Agents Med Chem (Discontinued) 11:40–47. https://doi.org/10.2174/187152211794519412 DOI

Bentley WE, Davis RH, Kompala DS (1991) Dynamics of induced CAT expression in E. coli. Biotechnol Bioeng 38:749–760. https://doi.org/10.1002/bit.260380709 PubMed DOI

Bhatwa A, Wang W, Hassan YI, Abraham N, Li XZ, Zhou T (2021) Challenges associated with the formation of recombinant protein inclusion bodies in Escherichia coli and strategies to address them for industrial applications. Front Bioeng Biotechnol 9:630551. https://doi.org/10.3389/fbioe.2021.630551 PubMed DOI PMC

Buchs J (2001) Introduction to advantages and problems of shaken cultures. Biochem Eng J 7:91–98. https://doi.org/10.1016/s1369-703x(00)00106-6 PubMed DOI

Chandrudu S, Simerska P, Toth I (2013) Chemical methods for peptide and protein production. Molecules 18:4373–4388. https://doi.org/10.3390/molecules18044373 PubMed DOI PMC

Czitrom V (1999) One-factor-at-a-time versus designed experiments. Am Stat 53(2):126–131. https://doi.org/10.1080/00031305.1999.10474445 DOI

de Groot NS, Ventura S (2006) Effect of temperature on protein quality in bacterial inclusion bodies. FEBS Lett 580:6471–6476. https://doi.org/10.1016/j.febslet.2006.10.071 PubMed DOI

Dolnik V (2008) Capillary electrophoresis of proteins 2005–2007. Electrophoresis 29:143–156. https://doi.org/10.1002/elps.200700584 PubMed DOI

Fosgerau K, Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Discov Today 20:122–128. https://doi.org/10.1016/j.drudis.2014.10.003 PubMed DOI

Francis DM, Page R (2010) Strategies to optimize protein expression in E. coli. Curr Protoc Protein Sci 61(1):21–25. https://doi.org/10.1002/0471140864.ps0524s61 DOI

Gao M, Ma C, Liu W, Zhu J, Tian H, Gao X, Yao W (2010) Production and purification of an analog of glucagon-like peptide-1 by auto-induction and on-column cleavage in Escherichia coli. World J Microbiol Biotechnol 26:1675–1682. https://doi.org/10.1007/s11274-010-0345-3 DOI

Gibisch M, Muller M, Tauer C, Albrecht B, Hahn R, Cserjan-Puschmann M, Striedner G (2024) A production platform for disulfide-bonded peptides in the periplasm of Escherichia coli. Microb Cell Fact 23:166. https://doi.org/10.1186/s12934-024-02446-6 PubMed DOI PMC

Gil-Garcia M, Navarro S, Ventura S (2020) Coiled-coil inspired functional inclusion bodies. Microb Cell Fact 19:117. https://doi.org/10.1186/s12934-020-01375-4 PubMed DOI PMC

Gomes L, Monteiro G, Mergulhao F (2020) The impact of IPTG induction on plasmid stability and heterologous protein expression by Escherichia Coli biofilms. Int J Mol Sci 21(2):576. https://doi.org/10.3390/ijms21020576 PubMed DOI PMC

Govender K, Naicker T, Lin J, Baijnath S, Chuturgoon AA, Abdul NS, Docrat T, Kruger HG, Govender T (2020) A novel and more efficient biosynthesis approach for human insulin production in Escherichia coli (E. coli). AMB Express 10:43. https://doi.org/10.1186/s13568-020-00969-w PubMed DOI PMC

Gruber CC, Babu VMP, Livingston K, Joisher H, Walker GC (2021) Degradation of the Escherichia coli essential proteins dapb and dxr results in oxidative stress, which contributes to lethality through incomplete base excision repair. mBio 13:e0375621. https://doi.org/10.1128/mbio.03756-21 PubMed DOI

Gutierrez-Gonzalez M, Farias C, Tello S, Perez-Etcheverry D, Romero A, Zuniga R, Ribeiro CH, Lorenzo-Ferreiro C, Molina MC (2019) Optimization of culture conditions for the expression of three different insoluble proteins in Escherichia coli. Sci Rep 9:16850. https://doi.org/10.1038/s41598-019-53200-7 PubMed DOI PMC

Hashemi A, Basafa M, Behravan A (2022) Machine learning modeling for solubility prediction of recombinant antibody fragment in four different E. coli strains. Sci Rep 12:5463. https://doi.org/10.1038/s41598-022-09500-6 PubMed DOI PMC

Heinisch L, Krause M, Roth A, Barth H, Schmidt H (2021) Cytotoxic effects of recombinant StxA2-His in the absence of its corresponding B-subunit. Toxins (Basel) 13(5):307. https://doi.org/10.3390/toxins13050307 PubMed DOI

Ilangala AB, Lechanteur A, Fillet M, Piel G (2021) Therapeutic peptides for chemotherapy: trends and challenges for advanced delivery systems. Eur J Pharm Biopharm 167:140–158. https://doi.org/10.1016/j.ejpb.2021.07.010

Incir I, Kaplan O (2024) Escherichia coli in the production of biopharmaceuticals. Biotechnol Appl Biochem 72:528–541. https://doi.org/10.1002/bab.2664

James J, Yarnall B, Koranteng A, Gibson J, Rahman T, Doyle DA (2021) Protein over-expression in Escherichia coli triggers adaptation analogous to antimicrobial resistance. Microb Cell Fact 20:13. https://doi.org/10.1186/s12934-020-01462-6 PubMed DOI PMC

Kasli IM, Thomas ORT, Overton TW (2019) Use of a design of experiments approach to optimise production of a recombinant antibody fragment in the periplasm of Escherichia coli: selection of signal peptide and optimal growth conditions. AMB Express 9:5. https://doi.org/10.1186/s13568-018-0727-8 PubMed DOI PMC

Kiefhaber T, Rudolph R, Kohler HH, Buchner J (1991) Protein aggregation in vitro and in vivo: a quantitative model of the kinetic competition between folding and aggregation. Biotechnology (NY) 9:825–829. https://doi.org/10.1038/nbt0991-825 DOI

Kornakov IA, Khasanshina ZR, Senichkina DA, Filipenko AA, Lunev IS, Drai RV (2023) Optimisation of induction conditions for a bacterial strain producing proinsulin aspart. Biological Products Prevention, Diagnosis, Treatment 23:219–230. https://doi.org/10.30895/2221-996X-2023-23-2-1-14 DOI

Kurien BT, Scofield RH (2012) Protein electrophoresis: methods and protocols. Totowa

Lamer T, Vederas JC (2023) Simplified cloning and isolation of peptides from “sandwiched” SUMO-peptide-intein fusion proteins. BMC Biotechnol 23:11. https://doi.org/10.1186/s12896-023-00779-5 PubMed DOI PMC

Latypov VF, Kornakov IA, Robustova SE, Khomutova OS, Rodionov PP (2020) Recombinant plasmid DNA pF646 encoding a hybrid polypeptide containing insulin aspart, and Escherichia coli strain – producer of the hybrid polypeptide containing insulin aspart. Patent RU2729353C1. Russia

Lau JL, Dunn MK (2018) Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem 26:2700–2707. https://doi.org/10.1016/j.bmc.2017.06.052 PubMed DOI

Lee SY (1996) High cell-density culture of Escherichia coli. Trends Biotechnol 14:98–95. https://doi.org/10.1016/0167-7799(96)80930-9 PubMed DOI

Li J, Jaitzig J, Hillig F, Sussmuth R, Neubauer P (2014) Enhanced production of the nonribosomal peptide antibiotic valinomycin in Escherichia coli through small-scale high cell density fed-batch cultivation. Appl Microbiol Biotechnol 98:591–601. https://doi.org/10.1007/s00253-013-5309-8 PubMed DOI

Li PZC, Li Q, Zhao W, Luo X (2021) Expression and optimizated of liraglutide precursor peptide GLP-1(7–37) K34R in Escherichia coli. Herald of Medicine 40:729–734. https://doi.org/10.3870/j.issn.1004-0781.2021.06.004 DOI

Li Y (2009) Carrier proteins for fusion expression of antimicrobial peptides in Escherichia coli. Biotechnol Appl Biochem 54:1–9. https://doi.org/10.1042/BA20090087 PubMed DOI

Liu M, Weiss MA, Arunagiri A, Yong J, Rege N, Sun J, Haataja L, Kaufman RJ, Arvan P (2018) Biosynthesis, structure, and folding of the insulin precursor protein. Diabetes Obes Metab 20(2):28–50. https://doi.org/10.1111/dom.13378 PubMed DOI PMC

Liu X, Li N, Jia M, Zhang S, Niu H, Li Q, Gu P (2020) The effects of kanamycin concentration on gene transcription levels in Escherichia coli. 3 Biotech 10:93. https://doi.org/10.1007/s13205-020-2100-2 PubMed DOI PMC

Ma B, Tu P, Zhao X, Zhang Y, Wang Y, Ma C, Ji Y, Li X, Abbas SA, Li M (2013) Expression and purification of optimized rolGLP-1, a novel GLP-1 analog, in Escherichia coli BL21(DE3) and its good glucoregulatory effect on type 2 diabetic mice. Curr Pharm Biotechnol 14:985–994. https://doi.org/10.2174/1389201014666131226155553 PubMed DOI

Malakar P, Venkatesh KV (2012) Effect of substrate and IPTG concentrations on the burden to growth of Escherichia coli on glycerol due to the expression of Lac proteins. Appl Microbiol Biotechnol 93:2543–2549. https://doi.org/10.1007/s00253-011-3642-3 PubMed DOI

Manandhar B, Ahn JM (2015) Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications. J Med Chem 58:1020–1037. https://doi.org/10.1021/jm500810s PubMed DOI

McDaniel LE, Bailey EG, Zimmerli A (1965) Effect of oxygen-supply rates on growth of Escherichia coli II. Comparison of results in shake flasks and 50-liter fermentor. Appl Microbiol 13:115–119. https://doi.org/10.1128/am.13.1.115-119.1965 PubMed DOI PMC

Mitraki A, Fane B, Haase-Pettingell C, Sturtevant J, King J (1991) Global suppression of protein folding defects and inclusion body formation. Science 253:54–58. https://doi.org/10.1126/science.1648264 PubMed DOI

Neubauer P, Hofmann K, Holst O, Mattiasson B, Kruschke P (1992) Maximizing the expression of a recombinant gene in Escherichia coli by manipulation of induction time using lactose as inducer. Appl Microbiol Biotechnol 36:739–744. https://doi.org/10.1007/BF00172185 PubMed DOI

Nguyen BN, Tieves F, Rohr T, Wobst H, Schopf FS, Solano JDM, Schneider J, Stock J, Uhde A, Kalthoff T, Jaeger KE, Schmitt L, Schwarz C (2021) Numaswitch: an efficient high-titer expression platform to produce peptides and small proteins. AMB Express 11:48. https://doi.org/10.1186/s13568-021-01204-w PubMed DOI PMC

Peroutka LRJ, Orcutt SJ, Strickler JE, Butt TR (2011) SUMO fusion technology for enhanced protein expression and purification in prokaryotes and eukaryotes. Methods Mol Biol 705:15–30. https://doi.org/10.1007/978-1-61737-967-3_2 DOI

Restrepo-Pineda S, Sanchez-Puig N, Perez NO, Garcia-Hernandez E, Valdez-Cruz NA, Trujillo-Roldan MA (2022) The pre-induction temperature affects recombinant HuGM-CSF aggregation in thermoinducible Escherichia coli. Appl Microbiol Biotechnol 106:2883–2902. https://doi.org/10.1007/s00253-022-11908-z PubMed DOI PMC

Rong Y, Jensen SI, Lindorff-Larsen K, Nielsen AT (2023) Folding of heterologous proteins in bacterial cell factories: cellular mechanisms and engineering strategies. Biotechnol Adv 63:108079. https://doi.org/10.1016/j.biotechadv.2022.108079 PubMed DOI

Sahoo A, Das PK, Dasu VV, Patra S (2024) Insulin evolution: a holistic view of recombinant production advancements. Int J Biol Macromol 277:133951. https://doi.org/10.1016/j.ijbiomac.2024.133951 PubMed DOI

Schein CH, Noteborn MH (1988) Formation of soluble recombinant proteins in Escherichia coli is favored by lower growth temperature. Biotechnology 6(3):291–294. https://doi.org/10.1038/nbt0388-291 DOI

Schellman JA (1997) Temperature, stability, and the hydrophobic interaction. Biophys J 73:2960–2964. https://doi.org/10.1016/S0006-3495(97)78324-3 PubMed DOI PMC

Shah JN, Guo GQ, Krishnan A, Ramesh M, Katari NK, Shahbaaz M, Abdellattif MH, Singh SK, Dua K (2022) Peptides-based therapeutics: emerging potential therapeutic agents for COVID-19. Therapie 77:319–328. https://doi.org/10.1016/j.therap.2021.09.007 PubMed DOI

Singh A, Upadhyay V, Upadhyay AK, Singh SM, Panda AK (2015) Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process. Microb Cell Fact 14:41. https://doi.org/10.1186/s12934-015-0222-8 PubMed DOI PMC

Song JM, An YJ, Kang MH, Lee YH, Cha SS (2012) Cultivation at 6–10 °C is an effective strategy to overcome the insolubility of recombinant proteins in Escherichia coli. Protein Expr Purif 82:297–301. https://doi.org/10.1016/j.pep.2012.01.020 PubMed DOI

Tahir S, Iqbal MM, Akhtar MW, Wang Q, Sun T, Sadaf S (2020) SUMO-fusion and autoinduction-based combinatorial approach for enhanced production of bioactive human interleukin-24 in Escherichia coli. Appl Microbiol Biotechnol 104:9671–9682. https://doi.org/10.1007/s00253-020-10921-4 PubMed DOI

Todaro B, Ottalagana E, Luin S, Santi M (2023) Targeting peptides: the new generation of targeted drug delivery systems. Pharm 15:1648. https://doi.org/10.3390/pharmaceutics15061648

Uhoraningoga A, Kinsella GK, Henehan GT, Ryan BJ (2018) The Goldilocks approach: a review of employing design of experiments in prokaryotic recombinant protein production. Bioengineering (Basel) 5(4):89. https://doi.org/10.3390/bioengineering5040089 PubMed DOI

Valdez-Cruz NA, Reynoso-Cereceda GI, Perez-Rodriguez S, Restrepo-Pineda S, Gonzalez-Santana J, Olvera A, Zavala G, Alagon A, Trujillo-Roldan MA (2017) Production of a recombinant phospholipase A2 in Escherichia coli using resonant acoustic mixing that improves oxygen transfer in shake flasks. Microb Cell Fact 16:129. https://doi.org/10.1186/s12934-017-0746-1 PubMed DOI PMC

Walsh G (2018) Biopharmaceutical benchmarks 2018. Nat Biotechnol 36:1136–1145. https://doi.org/10.1038/nbt.4305 PubMed DOI

Wang J, Chen L, Qin S, Xie M, Luo SZ, Li W (2024) Advances in biosynthesis of peptide drugs: technology and industrialization. Biotechnol J 19:e2300256. https://doi.org/10.1002/biot.202300256 PubMed DOI

Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C (2022) Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther 7:48. https://doi.org/10.1038/s41392-022-00904-4 PubMed DOI PMC

Winkler J, Seybert A, Konig L, Pruggnaller S, Haselmann U, Sourjik V, Weiss M, Frangakis AS, Mogk A, Bukau B (2010) Quantitative and spatio-temporal features of protein aggregation in Escherichia coli and consequences on protein quality control and cellular ageing. EMBO J 29:910–923. https://doi.org/10.1038/emboj.2009.412 PubMed DOI PMC

Wood TK, Peretti SW (1991) Effect of chemically-induced, cloned-gene expression on protein synthesis in E. Coli. Biotechnol Bioeng 38:397–412. https://doi.org/10.1002/bit.260380410 PubMed DOI

Wu GQ, Li LX, Ding JX, Wen LZ, Shen ZL (2008) High-level expression and novel purification strategy of recombinant thanatin analog in Escherichia coli. Curr Microbiol 57:95–101. https://doi.org/10.1007/s00284-008-9106-z PubMed DOI

Zhang ZX, Nong FT, Wang YZ, Yan CX, Gu Y, Song P, Sun XM (2022) Strategies for efficient production of recombinant proteins in Escherichia coli: alleviating the host burden and enhancing protein activity. Microb Cell Fact 21:191. https://doi.org/10.1186/s12934-022-01917-y PubMed DOI PMC